Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-modality Management Algorithm for Non-metastatic Pancreatic Cancer
NCT02626520Phase 2Terminated
- Sponsor
- Essentia Health
- Start
- May 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paclitaxel, fluorouracil, irinotecan in pancreatic ductal adenocarcinoma (PDAC), ampullary adenocarcinoma, sponsored by Essentia Health. Started May 2016; status: terminated.
02
Drugs
gemcitabinepaclitaxelfluorouracilirinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)ampullary adenocarcinoma
Beyond the preview
Go deeper on NCT02626520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626520.